Treatment Results in Patients with Drug Resistant Tuberculosis (MDR, pre-XDR, XDR) and HIV Infection in Stavropol Region
Open Access
- 5 July 2024
- journal article
- research article
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 102 (3) , 64-70
Abstract
The objective: to compare treatment effectiveness of drug resistant tuberculosis (MDR, pre-XDR, XDR) depending on the HIV status of patients in Stavropol Region from 2019 to 2022.Subjects and Methods. In a retrospective study, chemotherapy outcomes for pulmonary tuberculosis (TB) were evaluated with distribution by treatment regimens for MDR, pre-XDR, and XDR in 100 patients with drug resistant tuberculosis (MDR, pre-XDR, XDR and HIV infection (DR TB/HIV Group ) and 707 patients with drug resistant tuberculosis (MDR, pre-XDR, and XDR) (and negative HIV status (DR TB Group). The immune status of patients in DR TB/HIV Group and its impact on the effectiveness of tuberculosis treatment were analyzed.Results. Effective treatment (definitions are given according to the Guidelines) was statistically significantly more frequently registered in DR TB Group versus DR TB/HIV Group (59% and 48%, respectively, p<0.05). Treatment failure was statistically significantly more frequently registered in patients in DR TB/HIV Group versus DR TB Group (42% and 26%, respectively, p<0.05). In DR TB/HIV Group, the lowest effectiveness (33%) of tuberculosis treatment was noted in the patients with CD4 count below 200 cells/µL. Among those died, the median time to death from the start of tuberculosis treatment was 12 months in DR TB Group, 8 months in DR TB/HIV Group, and 4 months in the subgroup of patients with CD4 count below 100 cells/µL.Keywords
This publication has 10 references indexed in Scilit:
- Mortality rate and associated factors among patients co-infected with drug resistant tuberculosis/HIV at Mulago National Referral Hospital, Uganda, a retrospective cohort studyPLOS Global Public Health, 2023
- Diagnosis and treatment of tuberculosis in adults with HIVMedicine, 2022
- Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysisPharmacological Research, 2022
- Tuberculosis Situation in the Years of the COVID-19 Pandemic – 2020-2021Tuberculosis and Lung Diseases, 2022
- Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in RwandaThe American Journal of Tropical Medicine and Hygiene, 2021
- Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohortsThe International Journal of Tuberculosis and Lung Disease, 2021
- The multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosisTuberculosis and Lung Diseases, 2020
- Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysisThe Lancet, 2020
- EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTIONTuberculosis and Lung Diseases, 2017
- Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence settingThe International Journal of Tuberculosis and Lung Disease, 2012